| Abstrakt: |
A recent study conducted by researchers at the University Health Network in Toronto, Canada, explored the use of biomarkers to identify patients with non-small cell lung cancer (NSCLC) who would benefit from immune checkpoint blockade (ICB) therapy. The study analyzed the circulating metabolome of 55 patients with advanced NSCLC who were treated with ICB. The researchers identified eight metabolites, including glucosylceramide, that were significantly different between responders and non-responders to ICB therapy. Patients with higher baseline levels of glucosylceramide had significantly longer progression-free survival and overall survival compared to those with lower levels. Further research is needed to validate these findings and understand the underlying biological mechanisms. [Extracted from the article] |
